The randomized phase II GRIFFIN study showing that the addition of Darzalex (daratumumab) to bortezomib, lenalidomide, and dexamethasone induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation compared with VRd alone.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
